BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 24917122)

  • 1. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
    Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
    Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
    Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
    BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy.
    Komai Y; Numao N; Yoshida S; Matsuoka Y; Nakanishi Y; Ishii C; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Sep; 190(3):867-73. PubMed ID: 23542406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
    Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
    Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
    Numao N; Yoshida S; Komai Y; Ishii C; Kagawa M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Aug; 190(2):502-8. PubMed ID: 23473904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
    Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
    J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.
    Palmerola R; Smith P; Elliot V; Reese CT; Mahon FB; Harpster LE; Icitovic N; Raman JD
    Can J Urol; 2012 Dec; 19(6):6542-7. PubMed ID: 23228289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
    Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.
    Quentin M; Blondin D; Arsov C; Schimmöller L; Hiester A; Godehardt E; Albers P; Antoch G; Rabenalt R
    J Urol; 2014 Nov; 192(5):1374-9. PubMed ID: 24866597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer.
    Hara N; Okuizumi M; Koike H; Kawaguchi M; Bilim V
    Prostate; 2005 Feb; 62(2):140-7. PubMed ID: 15389803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
    Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
    Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
    Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
    J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study.
    De Nunzio C; Albisinni S; Freedland SJ; Miano L; Cindolo L; Finazzi Agrò E; Autorino R; De Sio M; Schips L; Tubaro A
    Urol Oncol; 2013 Oct; 31(7):997-1002. PubMed ID: 21925906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.